Biotech Values

[Summer2762]

Early evidence that docetaxel may continue to be relevant in CRPC in the near future. This is very important for OGXI investors.

In contrast, for pts treated with D, 10 (71%) had a decline in PSA; 6 (43%) with a > 50% maximum PSA decline. Of 6 pts with measurable disease, 2 (33%) had an objective response. The median time to progression for the D cohort was 129 days (range 60 – 294). Conclusions: Although the cohort size is small, and post-AA therapy was not randomized, these data provide preliminary support for the hypothesis that CRPC progressing on AA is cross-resistant to further androgen synthesis inhibition with keto. Contrary to other reports, prior treatment with AA does not appear to decrease the likelihood of subsequent response to D, but this observation requires prospective validation.

http://abstract.asco.org/AbstView_114_99396.html

Some additional comments can be found here

http://prostatecancerinfolink.net/2012/05/28/effects-of-ketoconazole-abiraterone-and-chemotherapy-in-men-with-crpc/